Death Receptor-Independent Apoptosis in Malignant Melanoma Induced by the Small-Molecule Immune Response Modifier Imiquimod
- 1 May 2004
- journal article
- clinical trial
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 122 (5) , 1266-1276
- https://doi.org/10.1111/j.0022-202x.2004.22528.x
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Regulation of Fas-Mediated Apoptosis by N-ras in MelanomaJournal of Investigative Dermatology, 2002
- Application of a Topical Immune Response Modifier, Resiquimod Gel, to Modify the Recurrence Rate of Recurrent Genital Herpes: A Pilot StudyThe Journal of Infectious Diseases, 2001
- Management of malignant melanoma: new developments in immune and gene therapyClinical and Experimental Dermatology, 2000
- Classical chemotherapy for metastatic melanomaClinical and Experimental Dermatology, 2000
- The Imidazoquinolines, Imiquimod and R-848, Induce Functional, but Not Phenotypic, Maturation of Human Epidermal Langerhans' CellsClinical Immunology, 2000
- Modulation of TH1 and TH2 Cytokine Production with the Immune Response Modifiers, R-848 and ImiquimodCellular Immunology, 1999
- Proteases to die forGenes & Development, 1998
- Immunomodulating and antiviral activities of the imidazoquinoline S-28463Antiviral Research, 1995
- Apoptosis in the Pathogenesis and Treatment of DiseaseScience, 1995
- Glycoprotein P3.58, associated with tumor progression in malignant melanoma, is a novel leukocyte activation antigenInternational Journal of Cancer, 1988